Posted by Michael Wonder on 23 Feb 2017
FDA expands indication for Revlimid (lenalidomide) as a maintenance treatment for patients with multiple myeloma following autologous haematopoietic stem cell transplant (auto-HSCT)
22 February 2017 - Approval enables Celgene to provide patients with treatment options across the multiple myeloma spectrum.
Celgene today announced that the U.S. FDA has expanded the existing indication for Revlimid (lenalidomide) 10 mg capsules to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT).
The expanded indication makes Revlimid the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.
